echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hutchison Medicine initiates phase I clinical trials of a new ERK inhibitor HMPL-295 in China

    Hutchison Medicine initiates phase I clinical trials of a new ERK inhibitor HMPL-295 in China

    • Last Update: 2021-08-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hutchison Medicine announced that it has initiated a phase I clinical trial of HMPL-295


    The study is a multi-center, open-label clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy characteristics of HMPL-295, and to determine the maximum tolerated dose in patients with advanced malignant solid tumors And the recommended dose of Phase II clinical study (RP2D)


    Hutchison Pharmaceuticals currently owns all rights of HMPL-295 worldwide


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.